TrkA Kinase Inhibitors Modulating NGF Receptor Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pain, inflammation, cancer, and neurodegenerative diseases often fail to effectively target the Trk/neutrophin pathway, particularly the TrkA receptor, leading to inadequate management of conditions such as chronic pain, inflammatory pain, and cancer.
Innovation Solution
Development of substituted six-membered aryl or heteroaryl benzamide compounds that act as Trk kinase inhibitors, specifically targeting the NGF receptor TrkA to modulate biological responses and inhibit TrkA activity, thereby treating associated diseases like pain, cancer, restenosis, atherosclerosis, psoriasis, and neurodegenerative disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for pain, inflammation, and cancer are used, then existing therapies can be administered, but they fail to effectively target the Trk/neutrophin pathway leading to inadequate management
Solution Approach 1:
The patent modifies the chemical structure of TrkA inhibitors by changing parameters such as introducing heteroaryl groups (imidazole, pyrimidine, triazole rings) at specific positions (R2 or R4) of the benzamide core. These structural parameter changes enhance the compound's ability to effectively target and inhibit the Trk/neutrophin pathway while maintaining versatility across multiple disease indications including pain, inflammation, and cancer.
2Reliability
If TrkA inhibitors are developed with improved efficacy, then therapeutic benefits for multiple conditions are achieved, but compound complexity increases
Solution Approach 1:
The patent segments the molecular structure into a core benzamide framework with distinct substitutable positions (R1-R8). By dividing the molecule into a core structure and modular substituents, the invention achieves improved therapeutic efficacy through targeted heteroaryl groups while maintaining manageable structural complexity through systematic variation at specific positions rather than complete molecular redesign.
Solution Approach 2:
The patent creates a universal benzamide core structure that can be applied across multiple disease indications (pain, inflammation, cancer, neurodegenerative diseases) by varying substituents at specific positions. This multi-functional approach allows a single structural platform to address multiple conditions, improving efficacy across the board while avoiding the need to develop entirely new compounds for each indication.
Data Source
AI summary
The present invention is directed to bicyclic heteroaryl benzamide compounds of formulas (I): which are tropomyos-in-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.